Hostname: page-component-7c8c6479df-p566r Total loading time: 0 Render date: 2024-03-29T06:51:10.882Z Has data issue: false hasContentIssue false

ESPASS study: Baseline characteristics of the included schizophrenic patients

Published online by Cambridge University Press:  16 April 2020

F. Rouillon
Affiliation:
PU-PH INSERM U669, Université Paris XI, Hopital Ste Anne, Paris Faculté de Médecine, Université René Descartes Paris V, Paris, France
J. Loze
Affiliation:
Bristol-Myers Squibb Company, Rueil-Malmaison, France
D. Leguay
Affiliation:
Ce.Sa.Me, Angers, France
I. Gasquet
Affiliation:
Maison Des Adolescents, INSERM U669, Université Paris XI, Hôpital Cochin AP-HP, Paris, France
R. Arnaud
Affiliation:
Bristol-Myers Squibb Company, Rueil-Malmaison, France
J. Azorin
Affiliation:
PU-PH Hôpital Sainte-Marguerite AP-HM, Faculté de Médecine de Marseille, Marseille, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective and aims

Better understanding of functional outcome predictors in schizophrenia has become key in order to face new challenges of the disease. The ESPASS survey aimed at evaluating the impact of antipsychotic therapy initiation or switch on psychosocial functioning in a sample of schizophrenic patients.

Methods:

The primary objective was to evaluate the change from baseline to 6 months in EAS total score (psychosocial functioning scale). Other criteria were the change in the IAQ total score, CGI-S, and PASAP (satisfaction with care)

Results (baseline visit)

5962 were included by 1169 investigators. Mean age was 37±12, 62% were male, 72% single, 62% were outpatients, 34% of the patients were on therapy for 10 years or more, 47% had paranoid schizophrenia subtype. Prior to baseline, 23% had no antipsychotic therapy, 25% had a conventional and 52% had an atypical antipsychotic. 8% of the total sample were naïve to antipsychotic therapy.

Obesity mostly affected patients treated with atypicals in comparison to conventional antipsychotics (20% vs. 15%). The EAS total score was 46±20 with lower sub-scores in following domains: money earning, management of belongings, social and private relationships. Mean CGI-S score was 4.7±1.0 and IAQ total score was 22±4. 26% of the patients participated in a psychosocial rehabilitation program for 3 to 4 years.

Conclusions:

While improving social functioning has clearly become key in the treatment of schizophrenia, only 26% of the patients were involved in an adequate rehabilitation program and 25% had a conventional antipsychotic.

Type
Poster Session 1: Schizophrenia and Other Psychosis
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.